Cancer Genomics Consortium
@cgconsortium.bsky.social
Cancer Genomics Consortium (CGC) is a 501(c)3 non-profit organization whose mission is to providing high quality education and promoting best practices in clinical cancer genomics.
Next week, the Cancer Genomics Consortium (CGC) will participate in Giving Tuesday, a global day of generosity, for the first time and we invite you to join us in supporting the future of cancer genomics. Learn how you can support the CGC here: buff.ly/Jzr5229
November 26, 2025 at 8:00 PM
Next week, the Cancer Genomics Consortium (CGC) will participate in Giving Tuesday, a global day of generosity, for the first time and we invite you to join us in supporting the future of cancer genomics. Learn how you can support the CGC here: buff.ly/Jzr5229
Join a global community shaping the future of clinical cancer genomics. As a CGC member, you’ll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide. buff.ly/tS7YP02
November 25, 2025 at 8:00 PM
Join a global community shaping the future of clinical cancer genomics. As a CGC member, you’ll connect with international genomics professionals, gain access to cutting-edge educational resources, and collaborate on initiatives that advance cancer genomics worldwide. buff.ly/tS7YP02
Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel?
A. MEN1
B. MEN2
C. MSH3
D. RET
A. MEN1
B. MEN2
C. MSH3
D. RET
November 25, 2025 at 3:03 PM
Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel?
A. MEN1
B. MEN2
C. MSH3
D. RET
A. MEN1
B. MEN2
C. MSH3
D. RET
Reminder to register for the upcoming webinar Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/lQIHd2h
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
November 19, 2025 at 3:03 PM
Reminder to register for the upcoming webinar Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/lQIHd2h
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel?
A. MEN1
B. MEN2
C. MSH3
D. RET
A. MEN1
B. MEN2
C. MSH3
D. RET
November 18, 2025 at 3:02 PM
Q27. A 16 y.o. female has hypercalcemia and hyperparathyroidism and family history of pituitary gland tumor and hyperparathyroidism in father. What would be likely finding in hereditary cancer panel?
A. MEN1
B. MEN2
C. MSH3
D. RET
A. MEN1
B. MEN2
C. MSH3
D. RET
Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?:
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
November 13, 2025 at 3:04 PM
Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?:
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Join us in congratulating Ninette Cohen, PhD, FACMG who is being featured in our November #CGCspotlight! Ninette is a member of the Communications Committee where she serves as chair of the website subcommittee. Learn more here: buff.ly/5sGAxRY
#CGCVolunteers #genomics #cancer #research #genetics
#CGCVolunteers #genomics #cancer #research #genetics
November 11, 2025 at 5:11 PM
Join us in congratulating Ninette Cohen, PhD, FACMG who is being featured in our November #CGCspotlight! Ninette is a member of the Communications Committee where she serves as chair of the website subcommittee. Learn more here: buff.ly/5sGAxRY
#CGCVolunteers #genomics #cancer #research #genetics
#CGCVolunteers #genomics #cancer #research #genetics
Registration Now Open: The Cancer Genomics Consortium (CGC) invites you to attend Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/9E1KZio
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
November 10, 2025 at 3:04 PM
Registration Now Open: The Cancer Genomics Consortium (CGC) invites you to attend Circulating Tumor DNA as Diagnostic Tool in Oncology on December 11, 2025. Click here to register: buff.ly/9E1KZio
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCVolunteers #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?:
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Type your answer in the chat below and come back next week for the answer and explanation!
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Type your answer in the chat below and come back next week for the answer and explanation!
November 6, 2025 at 3:01 PM
Q26. Which of the following abnormalities are defined as high risk in newly diagnosed patients with multiple myeloma?:
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Type your answer in the chat below and come back next week for the answer and explanation!
A. 1p32 gain
B. t(4;14)
C. t(11;14)
D. Trisomy 8
Type your answer in the chat below and come back next week for the answer and explanation!
Mark your calendar with #CGCAnnual2026—we look forward to seeing you in Houston next year!
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
November 5, 2025 at 3:03 PM
Mark your calendar with #CGCAnnual2026—we look forward to seeing you in Houston next year!
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics #molecular
The Education Committee is comprised of dedicated members who are committed to providing varied and interesting educational resources to our members throughout the year. We always welcome suggestions and feedback from members. Learn more about the committees here: buff.ly/q0FY6mo
#CGCVolunteers
#CGCVolunteers
November 4, 2025 at 3:03 PM
The Education Committee is comprised of dedicated members who are committed to providing varied and interesting educational resources to our members throughout the year. We always welcome suggestions and feedback from members. Learn more about the committees here: buff.ly/q0FY6mo
#CGCVolunteers
#CGCVolunteers
Final Day! Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics
October 30, 2025 at 2:05 PM
Final Day! Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics
Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4?
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
October 28, 2025 at 2:06 PM
Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4?
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
A quick reminder to join us tomorrow for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing." Click here to learn more and register today: buff.ly/Oxz6OQh
October 27, 2025 at 2:06 PM
A quick reminder to join us tomorrow for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing." Click here to learn more and register today: buff.ly/Oxz6OQh
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
October 23, 2025 at 2:05 PM
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
Join us next week for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing" on October 28, 2025. Click here to learn more and register today: buff.ly/Oxz6OQh
October 22, 2025 at 2:06 PM
Join us next week for "Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing" on October 28, 2025. Click here to learn more and register today: buff.ly/Oxz6OQh
Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4?
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
October 21, 2025 at 2:05 PM
Q25. A diffuse astrocytic glioma arising in 65-year-old patient is found to be IDH-wild type and H3-wild type, what is a defining genetic feature of glioblastoma, IDH-wild type, CNS WHO grade 4?
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
A. Gain of chromosome 10
B. TERT promoter mutation
C. EGFR gene amplification
D. B and C
The Cancer Genomics Consortium (CGC) and Oxford Nanopore Technologies invite you to attend Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing on October 28, 2025. Click here to learn more and to register today: buff.ly/Oxz6OQh
October 16, 2025 at 3:16 PM
The Cancer Genomics Consortium (CGC) and Oxford Nanopore Technologies invite you to attend Transforming Tumor Methylation Profiling with Oxford Nanopore Direct DNA Sequencing on October 28, 2025. Click here to learn more and to register today: buff.ly/Oxz6OQh
Join us in congratulating Teresa A. Smolarek, PhD, FACMG who is being featured in our October #CGCspotlight! Teresa is a member of the Genomic Diagnosis of Sarcoma Working Group and the Education Committee. Learn more here: buff.ly/UkJ5OXS
#CGCVolunteers #genomics #cancer #research #genetics
#CGCVolunteers #genomics #cancer #research #genetics
October 14, 2025 at 4:34 PM
Join us in congratulating Teresa A. Smolarek, PhD, FACMG who is being featured in our October #CGCspotlight! Teresa is a member of the Genomic Diagnosis of Sarcoma Working Group and the Education Committee. Learn more here: buff.ly/UkJ5OXS
#CGCVolunteers #genomics #cancer #research #genetics
#CGCVolunteers #genomics #cancer #research #genetics
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
October 13, 2025 at 2:05 PM
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
Don't miss out! The new letter from the CGC President is here, sharing the latest vision and updates for the future of the Cancer Genomics Consortium. Read the full message now: buff.ly/iuQLfTt
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
October 9, 2025 at 7:04 PM
Don't miss out! The new letter from the CGC President is here, sharing the latest vision and updates for the future of the Cancer Genomics Consortium. Read the full message now: buff.ly/iuQLfTt
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
Q24. Prader-Willi syndrome result from ______ in a majority of cases.
A. Imprinting defect
B. UPD15
C. Deletion
D. Path seq variant in UBE3A
A. Imprinting defect
B. UPD15
C. Deletion
D. Path seq variant in UBE3A
October 9, 2025 at 5:06 PM
Q24. Prader-Willi syndrome result from ______ in a majority of cases.
A. Imprinting defect
B. UPD15
C. Deletion
D. Path seq variant in UBE3A
A. Imprinting defect
B. UPD15
C. Deletion
D. Path seq variant in UBE3A
Please join us on Tuesday, October 14, for the monthly Collaborative Genomics Case Conference Webinar. This event is a partnership between the University of Wisconsin-Madison ICEP and the Cancer Genomics Consortium. Learn more here:
buff.ly/bKZ6sKX
#genomics #cancer #research #genetics
buff.ly/bKZ6sKX
#genomics #cancer #research #genetics
October 8, 2025 at 7:03 PM
Please join us on Tuesday, October 14, for the monthly Collaborative Genomics Case Conference Webinar. This event is a partnership between the University of Wisconsin-Madison ICEP and the Cancer Genomics Consortium. Learn more here:
buff.ly/bKZ6sKX
#genomics #cancer #research #genetics
buff.ly/bKZ6sKX
#genomics #cancer #research #genetics
CGC is dedicated to supporting the Early Career community with low trainee membership fees, outstanding early career programing, and incredible networking opportunities! CGC is the place to join for Early Career individuals in the Genetics and Genomics field.
October 7, 2025 at 2:04 PM
CGC is dedicated to supporting the Early Career community with low trainee membership fees, outstanding early career programing, and incredible networking opportunities! CGC is the place to join for Early Career individuals in the Genetics and Genomics field.
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
October 6, 2025 at 4:06 PM
Help shape the program for the Cancer Genomics Consortium 2026 Annual Meeting! The Cancer Genomics Consortium is soliciting proposals for invited sessions for the 17th Annual Meeting in Houston, TX.
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics
#CGCAnnual2026 #genomics #cancer #research #genetics #clinicaltesting #bioinformatics #cytogenetics